| Summary of Revenue by Geographic Areas and Segment |
The following tables summarize the revenue by segment and region for the periods presented (in thousands): | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | Nucleic Acid Production | | Biologics Safety Testing | | Total | | North America | $ | 23,872 | | $ | 6,767 | | $ | 30,639 | | Europe, the Middle East and Africa | 4,107 | | 4,288 | | 8,395 | | Asia Pacific | 3,023 | | 5,135 | | 8,158 | | Latin and Central America | 83 | | 122 | | 205 | | Total revenue | $ | 31,085 | | $ | 16,312 | | $ | 47,397 |
| | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2025 | | Nucleic Acid Production | | Biologics Safety Testing | | Total | | North America | $ | 45,846 | | $ | 14,062 | | $ | 59,908 | | Europe, the Middle East and Africa | 6,701 | | 8,572 | | 15,273 | | Asia Pacific | 7,170 | | 11,545 | | 18,715 | | Latin and Central America | 118 | | 233 | | 351 | | Total revenue | $ | 59,835 | | $ | 34,412 | | $ | 94,247 |
| | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2024 | | Nucleic Acid Production | | Biologics Safety Testing | | Total | | North America | $ | 25,436 | | $ | 6,801 | | $ | 32,237 | | Europe, the Middle East and Africa | 9,700 | | 3,946 | | 13,646 | | Asia Pacific | 19,415 | | 4,004 | | 23,419 | | Latin and Central America | 35 | | 86 | | 121 | | Total revenue | $ | 54,586 | | $ | 14,837 | | $ | 69,423 |
| | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2024 | | Nucleic Acid Production | | Biologics Safety Testing | | Total | | North America | $ | 51,714 | | $ | 13,894 | | $ | 65,608 | | Europe, the Middle East and Africa | 14,440 | | 8,571 | | 23,011 | | Asia Pacific | 34,326 | | 10,229 | | 44,555 | | Latin and Central America | 122 | | 306 | | 428 | | Total revenue | $ | 100,602 | | $ | 33,000 | | $ | 133,602 |
|
| Summary of Concentration of Revenue |
The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Revenue | | Accounts Receivable, net | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | | | June 30, 2025 | | December 31, 2024 | | 2025 | | 2024 | | 2025 | | 2024 | | | | | | | | Nacalai USA, Inc. | * | | 22.1 | % | | * | | 18.6 | % | | | | | | * | | 36.8 | % | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
____________________ *Less than 10%
|